$53.09
0.0%
Downside
Day's Volatility :2.87%
Upside
2.87%
49.52%
Downside
52 Weeks Volatility :56.92%
Upside
14.66%
Period | Biohaven Ltd | Index (Russel 2000) |
---|---|---|
3 Months | 55.45% | 0.0% |
6 Months | 29.59% | 0.0% |
1 Year | 77.71% | 0.0% |
3 Years | -61.55% | -27.4% |
Market Capitalization | 5.2B |
Book Value | $4.16 |
Earnings Per Share (EPS) | -9.3 |
Wall Street Target Price | 65.23 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -89.65% |
Return On Equity TTM | -193.67% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -774.4M |
Diluted Eps TTM | -9.3 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -8.88 |
EPS Estimate Next Year | -6.32 |
EPS Estimate Current Quarter | -1.77 |
EPS Estimate Next Quarter | -1.7 |
What analysts predicted
Upside of 22.87%
Sell
Neutral
Buy
Biohaven Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Biohaven Ltd | 1.88% | 29.59% | 77.71% | -61.55% | 16.8% |
Regeneron Pharmaceuticals, Inc. | -18.01% | -15.81% | -1.7% | 31.13% | 150.21% |
Biontech Se | -12.27% | 17.34% | 4.17% | -56.04% | 478.94% |
Alnylam Pharmaceuticals, Inc. | 2.34% | 76.9% | 60.41% | 45.24% | 198.24% |
Vertex Pharmaceuticals Incorporated | 10.04% | 20.33% | 30.51% | 156.8% | 152.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Biohaven Ltd | NA | NA | NA | -8.88 | -1.94 | -0.9 | NA | 4.16 |
Regeneron Pharmaceuticals, Inc. | 20.49 | 20.54 | 1.22 | 44.74 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -2.99 | -0.03 | -0.02 | NA | 85.17 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -1.87 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.27 | 0.19 | -0.03 | 0.12 | NA | 60.66 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Biohaven Ltd | Buy | $5.1B | 16.8% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $91.1B | 150.21% | 20.49 | 33.61% |
Biontech Se | Buy | $26.5B | 478.94% | 160.8 | -18.75% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.8B | 198.24% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $121.6B | 152.08% | 32.84 | -4.51% |
Insights on Biohaven Ltd
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 45.8% return, outperforming this stock by 109.0%
Vanguard Group Inc
Stifel Financial Corp
BlackRock Inc
HHG PLC
Suvretta Capital Management, LLC
State Street Corp
Biohaven Ltd’s price-to-earnings ratio stands at None
Read MoreOrganization | Biohaven Ltd |
Employees | 239 |
CEO | Dr. Vladimir Coric M.D. |
Industry | Health Technology |